Cole P L, Smith T W
Drug Intell Clin Pharm. 1986 Apr;20(4):267-70. doi: 10.1177/106002808602000403.
The narrow margin between therapeutic and toxic effects of digitalis glycosides renders patients taking these drugs particularly susceptible to serious consequences of accidental or deliberate overdosage, including life-threatening arrhythmias. Until recently, the treatment of digitalis intoxication has been largely supportive. In the past decade, however, digoxin-specific antibodies have been developed and have proven to be effective in rapidly reversing the electrophysiologic and metabolic manifestations of digitalis intoxication, both in vitro and in vivo. Enzymatic cleavage of the intact antibody population into Fab fragments results in a more rapidly effective and less immunogenic antidote to digitalis excess. More recently, monoclonal antibodies with high affinity and specificity for digoxin have been produced by the technique of somatic cell fusion; application of this technique to the production of antidigoxin antibodies has potential implications for the production of a highly purified homogeneous product, but this approach has not yet been tested clinically.
洋地黄糖苷治疗作用和毒性作用之间的安全范围很窄，这使得服用这些药物的患者特别容易受到意外或故意过量用药的严重后果影响，包括危及生命的心律失常。直到最近，洋地黄中毒的治疗在很大程度上都是支持性的。然而，在过去十年中，已开发出地高辛特异性抗体，并且已证明其在体外和体内均可有效快速逆转洋地黄中毒的电生理和代谢表现。将完整抗体群体酶解为Fab片段可产生一种对洋地黄过量更快速有效且免疫原性更低的解毒剂。最近，通过体细胞融合技术生产出了对地高辛具有高亲和力和特异性的单克隆抗体；将该技术应用于抗地高辛抗体的生产可能对生产高度纯化的均质产品具有潜在意义，但这种方法尚未经过临床测试。
